×
TDOC plunged approximately -27.2% during the regular session on Thursday, extending a sharp after-hours selloff that began Wednesday evening following its Q2 2026 earnings release. The primary catalyst: Q2 revenue of $606.9 million missed Wall Street's $615.4 million consensus, while BetterHelp segment sales dropped -12% year-over-year amid accelerating cash-pay customer erosion.
Tempus AI shares fell approximately 28.7% over the past 30 days, dropping from $58.31 on June 29 to $41.55 on July 29, 2026. The steep decline was triggered by the announcement of a $1.5 billion all-stock acquisition of Personalis, which raised integration and dilution concerns among investors.
EVH plunged -13.64% during regular trading Thursday, dropping from a prior close of $5.57 to an intraday low near $4.81, marking its steepest single-day decline in months. Citigroup analyst Daniel Grosslight downgraded Evolent Health from Buy to Sell, citing a less favorable risk/reward after the stock rallied more than +100% over the prior three months.
TEM shares tumbled -8.94% during Monday's regular session, falling from Friday's close of $52.47 to approximately $47.78, after opening sharply lower following premarket weakness. The primary catalyst is Tempus AI's announcement that it will acquire cancer-test maker Personalis (PSNL) in an all-stock deal valued at $1.5 billion, at $16.25 per share — a transaction viewed by investors as dilutive and costly for a company still reporting net losses.
Hinge Health (HNGE) shares surged approximately 30.7% over the last 30 days, climbing from $68.35 on June 15, 2026, to $89.31 by July 14, 2026. The rally was fueled by a series of analyst price-target upgrades, bullish Q2 user-engagement data, and growing confidence in the company's AI-driven margin expansion story.
10x Genomics shares surged roughly 44% over the past 30 days, climbing from approximately $28.84 to $41.60 and repeatedly touching new 52-week highs. The rally was fueled by a series of catalysts including the acquisition of Proteintech Genomics, a multi-year research partnership with Cleveland Clinic, and a wave of analyst price target increases.
HTFL shares tumbled -14.25% during Tuesday's regular session, falling from Friday's close of $35.65 to $30.57, as heavy selling pressure continued following the June 26 disclosure of CEO John Farquhar's $1.36 million insider stock sale. The CEO sold 38,900 shares at $35.00 on June 24 under a pre-arranged Rule 10b5-1 trading plan, a move that rattled investor confidence and triggered a sharp reassessment of the company's near-term prospects.
Simulations Plus (SLP) surged approximately 29% over the last 30 days, climbing from $14.10 on May 19 to $18.24 by June 18, 2026. The definitive acquisition agreement with Altaris for $18.50 per share in cash, announced in mid-June, served as the primary catalyst for the sharp upward move.
Veeva Systems reported total revenue of $882.9 million for the fiscal 2027 first quarter ended April 30, 2026, representing 16% year-over-year growth. Subscription services revenue reached $730.2 million, up 15% from the prior year.
Veeva Systems is scheduled to report fiscal 2027 first-quarter results on June 3, 2026. The company provided revenue guidance of $855 million to $858 million for the quarter.
Tempus AI reported Q1 2026 revenue growth of 36% year-over-year to $348.1 million, driven by diagnostics and data applications. Company raised full-year 2026 revenue guidance to $1.59–$1.60 billion, targeting ~$65 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
DOCS shares are down approximately 23% in premarket trading on May 14, 2026, following a post-earnings selloff that began after the close on May 13. Primary catalyst: Doximity issued fiscal year 2027 annual revenue guidance of $664M–$676M, falling well short of the Wall Street consensus near $697.4 million.
VEEV shares surged 10.11% to $171.75 in today's trading session from the previous close of $155.97. Primary catalyst: Announcement that VEEV will join the S&P 500 index effective May 7, replacing Coterra Energy ( CTRA ).
Shares of WAY are declining approximately 14.00% on Thursday, April 30, 2026, falling from a prior close of $25.27 to approximately $21.73 — approaching the stock's 52-week low of $21.09 set on April 10 — as Q1 2026 results released April 29 delivered a headline revenue beat that was immediately overshadowed by Q2 2026 sequential revenue guidance of flat to -1% growth, signaling that the momentum trajectory in healthcare payment software is decelerating materially.
CareCloud, Inc. (CCLD) delivers cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) tailored for medical practices. The company's model centers on subscription platforms that handle practice management, patient engagement, and billing, with AI-driven tools adding efficiency.
PHR shares are plunging approximately 26.64% in premarket trading on March 31, 2026, falling from a prior close of $11.41 to $8.37. The primary catalyst is a significant downward revision to fiscal 2027 revenue guidance, cutting the midpoint outlook by roughly $37 million.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
For the Physicians group companies, which include DYNT (Dynatronics), ANGO (AngioDynamics), AMEH (Apollo Medical Holdings), and OPRX (OptimizeRx), the past week has been marked by a significant increase in performance, with a collective gain of +4.41%. However, a deeper look into various indicators and metrics suggests a challenging road ahead for these stocks.
The Diabetes sector has been making headlines recently with a remarkable surge in performance, recording an impressive +11.13% increase over the past week. This surge has sparked considerable interest among investors and analysts alike. In this article, we'll delve into the details of this theme, focusing on the four key tickers that have been at the forefront of this trend: NURO, DRIO, ORGS, and DMAC.
During the previous week, the robot successfully generated a gain of +3.93% while trading TDOC (Teladoc Health Inc.), a medium volatility stock favored for active trading. Despite this commendable performance, recent technical indicators and earnings results indicate potential challenges ahead. In this article, we will analyze the bearish signals triggered by TDOC's Moving Average Convergence Divergence Histogram (MACD) and examine the company's latest earnings report.